Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

Approximately a quarter of individuals with primary sclerosing cholangitis experience moderate-severe pruritus.

The National Institutes of Health announced that it will end its funding of research that uses human fetal tissue.

Adjuvant systemic therapy was associated with improved rates of overall survival among patients who underwent surgical resection for MM.

Trump proposed sending money directly to Americans among other ideas in response to the end of Obamacare subsidies.

Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and ...

The US Department of Health and Human Services restored the Public Health Infrastructure Grants it had placed on hold.

Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high cure rates for non-melanoma ...

Rezpegaldesleukin may be an effective therapeutic option for adults with moderate to severe AD as well as those with comorbid ...

The CDC’s principal deputy director suggested the prospect of the US losing its measles elimination status was not a serious ...

Native American vs non-Native individuals showed a higher prevalence and incidence of statin-associated anti-HMHCR antibody IMNM.

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.